Clinical trials
Phase 1/2 Uterine Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 2 |
| 2004 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2022 | 1 |
| 2023 | 3 |
| 2024 | 2 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 6 |
| Terminated | 4 |
| Recruiting | 3 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Genmab | 2 |
| University Health Network, Toronto | 2 |
| Icahn School of Medicine at Mount Sinai | 1 |
| Incyte Corporation | 1 |
| Kineta Inc. | 1 |
| M.D. Anderson Cancer Center | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| National Cancer Institute (NCI) | 1 |
| Precision Biologics, Inc | 1 |
| Revolution Medicines, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Uterine Neoplasms | 17 |
| Uterine Cervical Neoplasms | 9 |
| Ovarian Neoplasms | 8 |
| Prostatic Neoplasms | 6 |
| Carcinoma, Non-Small-Cell Lung | 5 |
| Urinary Bladder Neoplasms | 5 |
| Breast Neoplasms | 4 |
| Colonic Neoplasms | 4 |
| Esophageal Neoplasms | 4 |
| Head and Neck Neoplasms | 4 |
Trials
Showing 76 to 17 of 17. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.